Until 2026, private weight-loss treatment in the UK effectively meant a weekly injection. In June 2026 the MHRA approved an oral form of semaglutide — the first GLP-1 tablet licensed here for weight management — and in August 2026 authorised orforglipron, a daily oral GLP-1, making the UK the first country in Europe to approve it.
Two oral options is not a footnote. It is the first genuine structural change to how these medicines are taken since they arrived.
How the Dosing Differs
Injections
- Once weekly, self-administered with a pre-filled pen
- Dose escalates every four weeks through a fixed ladder
- Needs refrigeration before first use, and careful handling when travelling
Oral semaglutide
- Once daily
- Steps of 1.5mg, 4mg, 9mg and 25mg, with a minimum of one month at each level
- Absorption is sensitive to timing — it needs an empty stomach and a wait before eating or drinking
That last point is the practical catch. A weekly injection asks for a few minutes once a week. A daily tablet with an absorption window asks for a small routine every morning, and skipping the routine reduces the dose you actually receive.
Effectiveness
Both routes deliver a GLP-1 receptor agonist and work the same way: slowing gastric emptying, acting on appetite signalling, and reducing how much you want to eat. Head-to-head comparisons between specific products and doses are still developing, and the honest position is that the choice today is driven more by tolerability, convenience and price than by a decisive efficacy gap.
Side Effects
The side-effect families are shared: nausea, vomiting, diarrhoea and constipation dominate, usually easing after the first weeks at each new dose. The 2026 MHRA guidance on severe acute pancreatitis applies to GLP-1 medicines generally, oral and injected alike.
One difference worth raising with a prescriber: a tablet taken daily reaches a different pattern of exposure from a weekly injection, and some people find one easier on the stomach than the other.
Cost — and Why It Is Too Early to Call
A tablet is a different manufacturing and distribution proposition from a cold-chain pen, and pharmacies price them separately. Early pricing in a new format is rarely where it settles, and neither oral option is routinely available on the NHS.
The comparison that actually matters is the cost of getting through a full course at the doses you are likely to need, not the headline price of month one. That is true whichever route you take, and it is more true with tablets, where four escalating strengths each carry their own price.
Which Should You Choose?
There is no universal answer, but there are useful tie-breakers:
- Needle aversion is a real and sufficient reason to prefer a tablet
- An unpredictable morning routine favours the weekly injection, because the absorption rules are easier to break than to follow
- Travel is simpler with tablets — no refrigeration, no sharps
- Existing tolerance counts for a lot: if you are established on an injection and doing well, switching format restarts a variable you had already solved
Discuss the switch with your prescriber rather than arranging it yourself. Transitioning between formats has its own dose mapping, and getting it wrong wastes weeks.